Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine-Reference-Cited by-同舟云学术

Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine

Published:2011-08-03 Issue:4 Volume:91 Page:643-644
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Lim Seah H.,Pathapati Srinivas,Langevin James,Hoot Andrew

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-011-1307-z.pdf

Reference5 articles.

1. Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383–3389

2. Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 26:4473–4479

3. Rummel MJ, Niederle N, Maschmeyer G et al (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphoma: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphoma, Germany). Blood 114:168–169

4. Kahl BS, Bartlett NL, Leonard JP et al (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin's lymphoma: results from a multicenter study. Cancer 116:106–114

5. Maung ZT, Wood AC, Jackson GH, Turner GE, Appleton AL, Hamilton PJ (1994) Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 88:649–652

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine;Annals of Hematology;2024-08-19

2. Infection risk and antimicrobial prophylaxis in bendamustine‐treated patients with indolent non‐Hodgkin lymphoma: An Australasian Lymphoma Alliance study;British Journal of Haematology;2024-03-14

3. Cytomegalovirus Occurrence and Time-to-onset Analysis Under Bendamustine With Anti-CD20 Antibodies Using the JADER Database;In Vivo;2024

4. Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience;Leukemia & Lymphoma;2022-10-12

5. Cytomegalovirus Reactivation After Bendamustine-Based Chemotherapy;Infectious Diseases in Clinical Practice;2021-02-19